Last reviewed · How we verify
IV Sodium Ferric Gluconate Complex
IV Sodium Ferric Gluconate Complex, marketed by Rambam Health Care Campus, is an iron replacement therapy currently available in the market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue.
At a glance
| Generic name | IV Sodium Ferric Gluconate Complex |
|---|---|
| Also known as | IV Ferrlecit |
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IV Iron in Acute Decompensated Heart Failure (PHASE4)
- IV Sodium Ferric Gluconate Complex in Patients Undergoing TAVI (PHASE4)
- Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment (PHASE2)
- Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients (PHASE4)
- Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents (PHASE4)
- Comparison Between Effects of Two Iron Preparations on Protein in the Urine (PHASE1)
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Sodium Ferric Gluconate Complex CI brief — competitive landscape report
- IV Sodium Ferric Gluconate Complex updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI